Salubris(SZ:002294) Xin Lang Cai Jing·2025-09-19 06:28Group 1 - The core point of the news is that Shenzhen Xinlitai Pharmaceutical Co., Ltd. experienced a stock decline of 5.14% on September 19, with a trading price of 51.70 yuan per share and a total market capitalization of 57.636 billion yuan [1] - The company was established on November 3, 1998, and went public on September 10, 2009. Its main business involves the research, production, and sales of pharmaceuticals and medical devices [1] - The revenue composition of the company is as follows: 81.69% from formulations, 8.54% from medical devices, 7.17% from raw materials, and 2.59% from other sources [1] Group 2 - From the perspective of fund holdings, one fund under Jianxin Fund has a significant position in Xinlitai, specifically the Jianxin CSI Innovative Drug Industry ETF (159835), which held 58,900 shares in the second quarter, accounting for 2.64% of the fund's net value [2] - The Jianxin CSI Innovative Drug Industry ETF was established on March 11, 2021, with a current scale of 106 million yuan. It has achieved a year-to-date return of 40.88% and a one-year return of 62.36% [2] - The fund manager, Gong Jiajia, has been in the position for 6 years and 212 days, with the fund's total asset scale at 606 million yuan. The best return during the tenure is 44.21%, while the worst return is -51.28% [2]